Growth hormone receptor blockade inhibits growth hormone-induced chemoresistance by restoring cytotoxic-induced apoptosis in breast cancer cells independently of estrogen receptor expression

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 6, 2012, Pages

  Minoia, Mariella ^a   Gentilin, Erica ^a   Molè, Daniela ^a   Rossi, Martina ^a   Filieri, Carlo ^a   Tagliati, Federico ^a   Baroni, Alessandra ^b   Ambrosio, Maria Rosaria ^a   Degli Uberti, Ettore ^a   Zatelli, Maria Chiara ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b SenTech Srl   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CYTOTOXIC AGENT; DNA; DOXORUBICIN; ESTROGEN RECEPTOR; GROWTH HORMONE; GROWTH HORMONE RECEPTOR; PEGVISOMANT; STRESS ACTIVATED PROTEIN KINASE;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CELL ACTIVATION; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL METABOLISM; CELL PROLIFERATION; CELL PROTECTION; CELL VIABILITY; CONTROLLED STUDY; DNA SYNTHESIS; DRUG CYTOTOXICITY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HORMONE ACTION; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BLOCKING; THERAPY RESISTANCE; TRANSCRIPTION INITIATION;

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BREAST NEOPLASMS; CELL DIVISION; CELL LINE, TUMOR; DOXORUBICIN; DRUG INTERACTIONS; DRUG RESISTANCE, NEOPLASM; FEMALE; GLUTATHIONE TRANSFERASE; HUMAN GROWTH HORMONE; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; RECEPTORS, ESTROGEN; RECEPTORS, SOMATOTROPIN; TRANSCRIPTIONAL ACTIVATION;

EID: 84861966371     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-3340     Document Type: Article

References (34)

1. Kleinberg DL, Wood TL, Furth PA, Lee AV 2009 Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions. Endocr Rev 30:51-74
2. Emerman JT, Leahy M, Gout PW, Bruchovsky N 1985 Elevated growth hormone levels in sera from breast cancer patients. Horm Metab Res 17:421-424 (Pubitemid 15043142)
3. Zhu T, Starling-Emerald B, Zhang X, Lee KO, Gluckman PD, Mertani HC, Lobie PE 2005 Oncogenic transformation of human mammary epithelial cells by autocrine human growth hormone. Cancer Res 65:317-324 (Pubitemid 40070824)
4. Kaulsay KK, Zhu T, Bennett W, Lee KO, Lobie PE 2001 The effects of autocrine human growth hormone (hGH) on human mammary carcinoma cell behavior are mediated via the hGH receptor. Endocrinology 142:767-777 (Pubitemid 32222426)
5. Chiesa J, Ferrer C, Arnould C, Vouyovitch CM, Diaz JJ, Gonzalez S, Mares P, Morel G, Wu ZS, Zhu T, Lobie PE, Mertani HC 2011 Autocrine proliferative effects of hGH are maintained in primary cultures of human mammary carcinoma cells. J Clin Endocrinol Metab 96:E1418-E1426
6. Zatelli MC, Minoia M, Molè D, Cason V, Tagliati F, Margutti A, Bondanelli M, Ambrosio MR, degli Uberti E 2009 Growth hormone excess promotes breast cancer chemoresistance. J Clin Endocrinol Metab 94:3931-3938
7. Coley HM 2008 Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. Cancer Treatment Rev 34:378-390
8. Cailleau R, Young R, Olivë M, Reeves WJ Jr 1974 Breast tumor cell lines from pleural effusions. J Natl Cancer Inst 53:661-674
9. Nagaraja GM, Othman M, Fox BP, Alsaber R, Pellegrino CM, Zeng Y, Khanna R, Tamburini P, Swaroop A, Kandpal RP 2006 Gene expression signatures and biomarkers of noninvasive and invasive breast cancer cells: comprehensive profiles by representational difference analysis, microarrays and proteomics. Oncogene 25:2328-2338
10. Zatelli MC, Tagliati F, Piccin D, Taylor JE, Culler MD, Bondanelli M, degli Uberti EC 2002 Somatostatin receptor subtype 1 selective activation reduces cell growth and calcitonin secretion in a human medullary thyroid carcinoma cell line. Biochem Biophys Res Commun 297:828-834
11. Tagliati F, Gentilin E, Buratto M, Molè D, degli Uberti EC, Zatelli MC 2010 Magmas, a gene newly identified as overexpressed in human and mouse ACTH-secreting pituitary adenomas, protects pituitary cells from apoptotic stimuli. Endocrinology 151:4635-4642
12. Hayes JD, Pulford DJ 1995 The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 30:445-600
13. Coecke S, Vanhaecke T, Foriers A, Phillips IR, Vercruysse A, Shephard EA, Rogiers V 2000 Hormonal regulation of glutathione Stransferase expression in co-cultured adult rat hepatocytes. J Endocrinol 166:363-371 (Pubitemid 30650573)
14. Kim J, Freeman MR 2003 JNK/SAPK mediates doxorubicin-induced differentiation and apoptosis in MCF-7 breast cancer cells. Breast Cancer Res Treat 79:321-328 (Pubitemid 36750939)
15. Lin KL, Su JC, Chien CM, Tseng CH, Chen YL, Chang LS, Lin SR 2010 Naphtho[1,2-b]furan-4,5-dione induces apoptosis and S-phase arrest of MDA-MB-231 cells through JNK and ERK signaling activation. Toxicol In Vitro 24:61-70
16. Brisken C, O'Malley B 2010 Hormone action in the mammary gland. Cold Spring Harb Perspect Biol 2:a003178
17. Lee AV, Jackson JG, Gooch JL, Hilsenbeck SG, Coronado-Heinsohn E, Osborne CK, Yee D 1999 Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Mol Endocrinol 13:787-796 (Pubitemid 30645331)
18. Xu J, Zhang Y, Berry PA, Jiang J, Lobie PE, Langenheim JF, Chen WY, Frank SJ 2011 Growth hormone signaling in human T47D breast cancer cells: potential role for a growth hormone receptor-prolactin receptor complex. Mol Endocrinol 25:597-610
19. Johnson KJ, Peck AR, Liu C, Tran TH, Utama FE, Sjolund AB, Schaber JD, Witkiewicz AK, Rui H 2010 PTP1B suppresses prolactin activation of Stat5 in breast cancer cells. Am J Pathol 177:2971-2983
20. Ballestar E, Paz MF, Valle L, Wei S, Fraga MF, Espada J, Cigudosa JC, Huang TH, EstellerM2003 Methyl-CpG binding proteins identify novel sites of epigenetic inactivation in human cancer. EMBO J 22:6335-6345 (Pubitemid 37522590)
21. Fornari FA, Randolph JK, Yalowich JC, Ritke MK, Gewirtz DA 1994 Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells. Mol Pharmacol 45:649-656 (Pubitemid 24139191)
22. Sau A, Pellizzari Tregno F, Valentino F, Federici G, Caccuri AM 2010 Glutathione transferases and development of new principles to overcome drug resistance. Arch Biochem Biophys 500:116-122
23. Kim SK, Novak RF 2007 The role of intracellular signaling in insulin-mediated regulation of drug metabolizing enzyme gene and protein expression. Pharmacol Ther 113:88-120 (Pubitemid 44969928)
24. Grgurevich S, Greene FE 1995 Selective suppression of glutathione S-transferase activities in rat primary hepatocytes by growth hormone. Pharmacology 51:13-23
25. Mingo-Sion AM, Marietta PM, Koller E, Wolf DM, Van Den Berg CL 2004 Inhibition of JNK reduces G2/M transit independent of p53, leading to endoreduplication, decreased proliferation, and apoptosis in breast cancer cells. Oncogene 23:596-604 (Pubitemid 38175015)
26. Devos R, Guisez Y, Van der Heyden J, White DW, Kalai M, Fountoulakis M, Plaetinck G 1997 Ligand-independent dimerization of the extracellular domain of the leptin receptor and determination of the stoichiometry of leptin binding. J Biol Chem 272:18304-18310 (Pubitemid 27306421)
27. Constantinescu SN, Keren T, Socolovsky M, Nam H, Henis YI, Lodish HF 2001 Ligand-independent oligomerization of cell-surface erythropoietin receptor is mediated by the transmembrane domain. Proc Natl Acad Sci USA 98:4379-4384 (Pubitemid 32294985)
28. Gadd SL, Clevenger CV 2006 Ligand-independent dimerization of the human prolactin receptor isoforms: functional implications. Mol Endocrinol 20:2734-2746 (Pubitemid 44833532)
29. Bogorad RL, Courtillot C, Mestayer C, Bernichtein S, Harutyunyan L, Jomain JB, Bachelot A, Kuttenn F, Kelly PA, Goffin V, Touraine P, Benign Breast Diseases Study Group 2008 Identification of a gain-of-function mutation of the prolactin receptor in women with benign breast tumors. Proc Natl Acad Sci USA 105:14533-14538
30. Courtillot C, Chakhtoura Z, Bogorad R, Genestie C, Bernichtein S, Badachi Y, Janaud G, Akakpo JP, Bachelot A, Kuttenn F, Goffin V, Touraine P, Benign Breast Diseases Study Group 2010 Characterization of two constitutively active prolactin receptor variants in a cohort of 95 women with multiple breast fibroadenomas. J Clin Endocrinol Metab 95:271-279
31. Goffin V, Bogorad RL, Touraine P 2010 Identification of gain-of-function variants of the human prolactin receptor. Methods Enzymol 484:329-355
32. Stuhlmann-Laeisz C, Lang S, Chalaris A, Krzysztof P, Enge S, Eichler J, Klingmüller U, Samuel M, Ernst M, Rose-John S, Scheller J 2006 Forced dimerization of gp130 leads to constitutive STAT3 activation, cytokine-independent growth, and blockade of differentiation of embryonic stem cells. Mol Biol Cell 17:2986-2995 (Pubitemid 43993503)
33. Wang X, Chao L, Li X, Ma G, Chen L, Zang Y, Zhou G 2010 Elevated expression of phosphorylated c-Jun NH2-terminal kinase in basal-like and "triple-negative" breast cancers. Hum Pathol 41:401-406
34. Mira JP, Benard V, Groffen J, Sanders LC, Knaus UG 2000 Endogenous, hyperactive Rac3 controls proliferation of breast cancer cells by a p21-activated kinase-dependent pathway. Proc Natl Acad Sci USA 97:185-189 (Pubitemid 30055805)